A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

Name: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
Published: 2024
License: Public Domain

ViiV Healthcare · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

hiv hiv-infections safety

hiv infections, cabotegravir (cab), new formulation of cab la, cab la, hiv, 4-month dosing interval (q4m), safety, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

Related documents